Releases Geral
Bright Peak Therapeutics to Participate in 43rd Annual J.P. Morgan Healthcare Conference
AGÊNCIA DE COMUNICAÇÃO Conteúdo de responsabilidade da empresa 6 de janeiro de 2025
Bright Peak Therapeutics, Inc.
BASEL, Switzerland and SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) — Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced that Fredrik Wiklund, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14th, 2025, at 2:30 p.m. Pacific Time. The Company will also participate in 1-on-1 investor meetings during the conference.
About Bright Peak Therapeutics
Bright Peak Therapeutics is a clinical-stage biotechnology company pioneering multifunctional immunotherapies to treat cancer. Leveraging innovative protein engineering and a proprietary chemical protein synthesis and conjugation platform, Bright Peak is building a robust pipeline of first-in-class multifunctional molecules. The company’s lead program, BPT567, is a bifunctional PD1-IL18 immunoconjugate currently in Phase 1/2a clinical trials. With headquarters in Basel, Switzerland, and San Diego, CA, Bright Peak is backed by top-tier healthcare investors. For more information, visit www.brightpeaktx.com.
Contact:
info@brightpeaktx.com
A OESP nao e(sao) responsavel(is) por erros, incorrecoes, atrasos ou quaisquer decisoes tomadas por seus clientes com base nos Conteudos ora disponibilizados, bem como tais Conteudos nao representam a opiniao da OESP e sao de inteira responsabilidade da GlobeNewswire
Leia também
-
Releases Geral OPEN Health and Nested Knowledge announce strategic research collaboration to leverage AI technologies for evidence synthesis
11 de dezembro de 2023Open Health London, Dec. 11, 2023 (GLOBE NEWSWIRE) — London, UK December 11, 2023 OPEN Health, a preeminent global provider of consulting, HEOR and market access, patient engagement, and
Saiba Mais -
Releases Geral Implante zigomático garante tratamento ágil a pacientes
13 de março de 2024Belo Horizonte (MG)--(DINO - 13 mar, 2024) - Os dentes podem ser danificados por diversos fatores ao longo da vida. Muitas vezes acabam sendo extraídos ou caem. Apesar diss
Saiba Mais -
Releases Geral Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S.
1 de outubro de 2024This first-to-market launch showcases Tevas proven strengths in complex generic formulations and enhances Tevas strategic goal of sustaining a generic powerhouse.Octreotide
Saiba Mais